St Jude Medical and Thoratec have announced that the Boards of Directors of both companies have unanimously approved a definitive agreement under which St. Jude Medical will acquire all of the outstanding shares of Thoratec for $63.50 per share in a cash transaction valued at approximately $3.4 billion, net of cash acquired. The transaction is expected to be completed in the fourth quarter of 2015.
A press release reports that the combination of complementary product lines of St. Jude Medical and Thoratec will offer the most comprehensive portfolio of products for the management and treatment of heart failure.
Daniel J Starks, chairman, president and chief executive officer of St Jude Medical, says: “Thoratec’s strong core business and rich portfolio of new products complement St Jude Medical’s innovation-based growth strategy and will benefit patients, customers, employees and shareholders of both companies. The addition of Thoratec’s leading ventricular assist device portfolio expands and enhances St Jude Medical’s established presence in heart failure therapies. We look forward to welcoming Thoratec employees to our company at such an exciting time in our history.”
“Thoratec is pleased to join St Jude Medical as we create a company that’s uniquely positioned to advance treatment options for patients living with heart failure,” said D Keith Grossman, president and chief executive officer of Thoratec. “By combining the capabilities and leading technologies of both companies, we will be able to expand access, reduce costs and advance heart failure therapies on a global basis. Our employees and customers have worked together tirelessly over many years to create the market leader Thoratec has become. It is gratifying to see the creation of a combined product platform and capability with St Jude Medical that will fulfil the promise of our products to many, many more patients in the years to come.”